A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination Gemcitabine and Capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer.

Trial Profile

A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination Gemcitabine and Capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Tertomotide (Primary) ; Capecitabine; Gemcitabine; Sargramostim
  • Indications Pancreatic cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms TeloVac
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2014 Status changed from recruiting to discontinued, according to the article published in Lancet Oncology.
    • 30 May 2014 Predictive biomarker analysis presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top